As of March 31, 2025, Tyra had cash, cash equivalents, and marketable securities of $318.9M. The company’s current cash, cash equivalents and marketable securities are expected to allow TYRA to execute on its plans through at least 2027. “In 2025, we are focused on clinical execution across our portfolio of next-generation precision therapies for oncology and skeletal dysplasia. We continued to advance TYRA-300 for ACH and intermediate risk non-muscle invasive bladder cancer and will begin dosing in BEACH301 and SURF302 in Q2,” stated CEO Todd Harris. “In addition, our SURF431 study is now underway, and we dosed the first HCC patient with TYRA-430, our oral FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Oncology stocks ‘bearing the brunt’ of Prasad news, says Oppenheimer
- Tyra Bioscience’s Promising Clinical Developments and Strong Financial Health Justify Buy Rating
- Mitchell Kapoor Issues Buy Rating for Tyra Bioscience Due to TYRA-300’s Potential in NMIBC and ACH Markets
- Tyra Biosciences Advances Precision Medicine Pipeline
- Tyra Biosciences price target lowered to $28 from $29 at BofA